Sunovion scores on PhI­II Parkin­son's study, shoot­ing for show­down with Acor­da; Puma out-li­cens­es ner­a­tinib to Is­raeli biotech

Sunovion Phar­ma­ceu­ti­cals has post­ed pos­i­tive top-line da­ta from their Phase III study for OFF episodes of Parkin­son’s dis­ease. Ac­cord­ing to re­searchers apo­mor­phine hit the pri­ma­ry: a sta­tis­ti­cal­ly sig­nif­i­cant mean re­duc­tion in the Move­ment Dis­or­der So­ci­ety Uni­fied Parkin­son’s Dis­ease Rat­ing Scale (MDS-UP­DRS) Part III score. They added that the drug al­so scored on a key sec­ondary. Sunovion now plans to hus­tle the drug to the FDA soon, which may well set up a con­fronta­tion with a ri­val drug from the strug­gling Acor­da $ACOR, now ru­mored to be on the sales block.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.